Relugolix

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H27F2N7O5S
Molecular Weight	623.63
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5

InChI

InChIKey=AOMXMOCNKJTRQP-UHFFFAOYSA-N

InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)

HIDE SMILES / InChI

Molecular Formula	C29H27F2N7O5S
Molecular Weight	623.63
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214846s002lbl.pdf |https://pubmed.ncbi.nlm.nih.gov/36331779 |https://www.ncbi.nlm.nih.gov/pubmed/30937733 | https://www.ncbi.nlm.nih.gov/pubmed/26502357 | https://pubmed.ncbi.nlm.nih.gov/35866612

Relugolix (TAK-385) is an orally active nonpeptide gonadotropin-releasing hormone (GnRH) that binds to human GnRH receptors with subnanomolar affinity. Relugolix was demonstrated to act as a classic competitive antagonist of GnRH binding, but the exact molecular mechanism of that antagonism remains unknown. This drug is being developed as a treatment for various sex hormone related disorders. Based on the phase III HERO trial results, relugolix (Orgovyx) received Food and Drug Administration approval for adult patients with advanced prostate cancer. An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of heavy menstrual bleeding associated with uterine fibroids in the USA and management of moderate to severe symptoms of uterine fibroids in the EU.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Gonadotropin-releasing hormone receptor 41 Target ID: CHEMBL1855 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21657270	Antagonist 2849		0.08 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Prostate cancer 186 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	Primary	Approved 8583	ORGOVYX Approved Use Treatment of adult patients with advanced prostate cancer Launch Date 2020
Menstrual bleeding associated with uterine leiomyomas (fibroids) 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214846s002lbl.pdf	Primary	Approved 8583	MYFEMBREE Approved Use Indicated in premenopausal women for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). Launch Date 2021
Pain associated with endometriosis 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214846s002lbl.pdf	Primary	Approved 8583	MYFEMBREE Approved Use Indicated in premenopausal women for the management of moderate to severe pain associated with endometriosis. Launch Date 2021

C_max

Value	Dose	Co-administered	Analyte	Population
0.12 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.56 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1.61 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
3.74 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
9.46 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
32.9 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1.34 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
5.06 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
19 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.05 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
8.2 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
21.8 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
19.59 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=38	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: ESTRADIOL	ESTRADIOL	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
8.884 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=38	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: ESTRADIOL	ESTRADIOL	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED
12.5 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.43 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.6 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11.65 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=49	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.92 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=49	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=50	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.4 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=50	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
26 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214846s000lbl.pdf#page=19 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=6	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: ESTRADIOL	ESTRADIOL	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
125 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03085095	360 mg single, oral dose: 360 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
46.4 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03085095	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.97 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
8.44 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
18.05 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
45.25 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
107.67 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
293.45 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
35.34 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
18.16 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
58.65 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
19.6 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
58.68 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
119.04 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
168.5 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=38	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: ESTRADIOL	ESTRADIOL	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
104.6 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=38	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: ESTRADIOL	ESTRADIOL	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED
123 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
84.1 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
116 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
93.4 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=49	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
144.6 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=49	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
109 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=50	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
163 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=50	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
198.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214846s000lbl.pdf#page=19 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=6	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: ESTRADIOL	ESTRADIOL	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
663 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03085095	360 mg single, oral dose: 360 mg route of administration: Oral experiment type: SINGLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
373 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03085095	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RELUGOLIX plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
6.6 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
14.18 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
15.15 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
16.23 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
16.49 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
15.64 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	RELUGOLIX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
32% OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda#page=48_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=6			RELUGOLIX plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	Disc. AE: atrioventricular block, cardiac failure... AEs leading to discontinuation/dose reduction: atrioventricular block (severe, 0.3%) cardiac failure (severe, 0.3%) hemorrhage (severe, 0.3%) abdominal pain (0.3%) pneumonia (0.3%) fracture (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf

AEs

AE	Significance	Dose	Population
abdominal pain	0.3% Disc. AE	360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
fracture	0.3% Disc. AE	360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
pneumonia	0.3% Disc. AE	360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
atrioventricular block	severe, 0.3% Disc. AE	360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
cardiac failure	severe, 0.3% Disc. AE	360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
hemorrhage	severe, 0.3% Disc. AE	360 mg 1 times / day multiple, oral Highest studied dose\|Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 1057 P-gp 1741 BCRP 910 CYP1A2 2153 BSEP 550 MATE2-K 77 CYP2B6 926 CYP2C19 2057 OATP1B1 1079 OATP1B3 961 OAT1 725 OAT3 747 MATE1 415 OCT2 779	P-gp 2052 BCRP 697 OATP1B1 503 CYP2C8 810 OATP1B3 435	CYP3A 142 CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=41 Page: 41.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83 \| 84	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=41 Page: 41 \| 84	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=41 Page: 41 \| 84	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=41 Page: 41 \| 84	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=41 Page: 41 \| 84	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=41 Page: 41 \| 84	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 83	weak
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=43 Page: 41 \| 43 \| 84	yes [IC50 10.9 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 43 \| 83	yes [IC50 24.9 uM]
MATE2-K 77	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=43 Page: 41 \| 43 \| 84	yes [IC50 3.75 uM]
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40.0	yes
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=84 Page: 40 \| 83 \| 84	yes	yes (co-administration study) Comment: Decreased Midazolam AUC and Cmax by 17.7% and 25.7% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=84 Page: 40 \| 83 \| 84

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40 \| 74	minor
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 Page: 40.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=74 Page: 74.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=74 Page: 74.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=68 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=83 Page: 40 \| 68 \| 74 \|83	yes	yes (co-administration study) Comment: Erythromycin increased AUC and Cmax by 6.2-fold, Rifampicin decreased AUC by 55% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=68 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=83 Page: 40 \| 68 \| 74 \|83
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=68 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=83 Page: 40 \| 68 \| 75 \| 83	yes	yes (co-administration study) Comment: Erythromycin increased AUC and Cmax by 6.2-fold, Rifampicin decreased AUC by 55% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=40 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=68 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=83 Page: 40 \| 68 \| 75 \| 83

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf#page=32 Page: 32.0

PubMed

Title	Date	PubMed
Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.	2011-07-28	21657270

Sample Use Guides

In Vivo Use Guide

Prostate cancer: recommended dosage: a loading dose of 360 mg on the first day of treatment followed by 120 mg taken orally once daily, at approximately the same time each day

Route of Administration: Oral

In Vitro Use Guide

In vitro, in the absence of serum (FBS), TAK-385 bound to human, monkey and rat GnRH receptors with IC50 values of 0.12, 0.15 and 2900 nM, respectively (Study# TAK-385- 00090). Binding affinities decreased by 3-fold in the presence of 40% FBS for all GnRH receptors; nevertheless, TAK-385 bound to the human GnRH receptor with an IC50 value of 0.33 nM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:20:08 GMT 2025` Edited by `admin` on `Mon Mar 31 20:20:08 GMT 2025`
Record UNII	P76B05O5V6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Relugolix [INN]

Preferred Name

English

Relugolix

Official Name

English

Myfembree component relugolix

Brand Name

English

Relugolix [WHO-DD]

Common Name

English

Relugolix [JAN]

Common Name

English

TAK-385

Code

English

Relugolix [ORANGE BOOK]

Common Name

English Albanian

Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N?-methoxy-

Systematic Name

English

Orgovyx

Brand Name

English

1-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea

Systematic Name

English

Relugolix [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C63347